Clinical Research on Alzheimer's Disease: Progress and Perspectives.
10.1007/s12264-018-0249-z
- Author:
Bin-Lu SUN
1
;
Wei-Wei LI
1
;
Chi ZHU
1
;
Wang-Sheng JIN
1
;
Fan ZENG
1
;
Yu-Hui LIU
1
;
Xian-Le BU
1
;
Jie ZHU
1
;
Xiu-Qing YAO
2
;
Yan-Jiang WANG
3
Author Information
1. Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing, 400042, China.
2. Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing, 400042, China. dryaoxq@163.com.
3. Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing, 400042, China. yanjiang_wang@tmmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
5-HT6 receptor antagonist;
Alzheimer’s disease;
Amyloid-beta;
BACE1 inhibitor;
Biomarker;
Immunotherapy;
Positron emission tomographic imaging;
Primary prevention;
Tau
- MeSH:
Alzheimer Disease;
diagnosis;
physiopathology;
therapy;
Animals;
Biomarkers;
blood;
Biomedical Research;
methods;
Disease Progression;
Humans;
Magnetic Resonance Imaging
- From:
Neuroscience Bulletin
2018;34(6):1111-1118
- CountryChina
- Language:English
-
Abstract:
Alzheimer's disease (AD), the most common type of dementia, is becoming a major challenge for global health and social care. However, the current understanding of AD pathogenesis is limited, and no early diagnosis and disease-modifying therapy are currently available. During the past year, significant progress has been made in clinical research on the diagnosis, prevention, and treatment of AD. In this review, we summarize the latest achievements, including diagnostic biomarkers, polygenic hazard score, amyloid and tau PET imaging, clinical trials targeting amyloid-beta (Aβ), tau, and neurotransmitters, early intervention, and primary prevention and systemic intervention approaches, and provide novel perspectives for further efforts to understand and cure the disease.
